<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947555</url>
  </required_header>
  <id_info>
    <org_study_id>PTEBEL 01/2015</org_study_id>
    <nct_id>NCT02947555</nct_id>
  </id_info>
  <brief_title>Cardiovascular Risk Assesment in Diabetic Patients Via Lens Autofluorecscence Detection</brief_title>
  <acronym>CRADILA</acronym>
  <official_title>Cardiovascular Risk Assesment in Diabetic Patients Via Lens Autofluorecscence Detection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Gergő Molnár</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bajcsy-Zsilinszky Kórház</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Petz Aladar County Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderlich Egészségcentrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Semmelweis University Heart and Vascular Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Polytech Hungaria Kft.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of lens autofluorescence will be compared in diabetic and non diabetic patients
      with/without atherosclerotic vascular diseases to evaluate if it is associated with the risk
      of cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rate of lens autofluorescensce is associated with the accumulation of advanced glication
      endproducts (AGE).The concetration of AGE increases with age but is also higher in diabetic
      patients. There is evidence that diabetes could be diagnosed via the detection of lens
      autofluorescence. The investigators are planning a cross sectional clinical trial to evaluate
      if the rate of lens autofluorescence could be associated with the clinical appearance of
      atherosclerotic vascular diseases in diabetic/non-diabetic patients and in patients who
      already had atherosclerotic vascular events and patients without previous atherosclerotic
      events. The cardiovascular and metabolic histoty of patients will be evaluated using a
      questionaire. Antropometrical data, blood pressure, heart rate, glucose metabolism, serum
      lipid profile, CRP, serum creatinine (eGFR) will be assased. ClearPath DS-120
      biomicroscopical optical system (Freedom Meditech, San Diego, CA, USA) will be used for the
      measurment of lens autofluorescence. The measurement will be performed on one eye. Data of
      the different patient groups will be compared using ANOVA, a value of p&lt;0.05 will be
      considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of lens autofluorescence with atherosclerotic vascular events</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with the occurrance of atherosclerotic vascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of lens autofluorescence with the perscene of diabetes</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with the persence of diabetes type 2 diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of lens autofluorescence with renal function</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with renal function (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of lens autofluorescence with glucose metabolism parameteres</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with glucose metabolism parameteres (ex. HBA1C, HOMA IR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of lens autofluorescence with lipid profile</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with serum lipid values (serum total cholesterol, triglycerids, LDL, HDL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of lens autofluorescence with CRP</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with CRP level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of lens autofluorescence with antropoetric parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Measurement of the autofluorescence of lens proteins and assessement of its association with antropometric parameteres (body weight, height, BMI, waist-hip ratio)</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Diabetic Patients With/Without Atherosclerotic Diseases</condition>
  <arm_group>
    <arm_group_label>DM+/AT+</arm_group_label>
    <description>Patients with type 2 diabetes mellitus and atherosclerotic event in history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM+/AT-</arm_group_label>
    <description>Patients with type 2 diabetes mellitus without atherosclerotic event in history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM-/AT+</arm_group_label>
    <description>Non-diabetic patients with atherosclerotic event in history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM-/AT-</arm_group_label>
    <description>Non-diabetic patients without atherosclerotic event in history</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non interventional</intervention_name>
    <arm_group_label>DM+/AT+</arm_group_label>
    <arm_group_label>DM+/AT-</arm_group_label>
    <arm_group_label>DM-/AT+</arm_group_label>
    <arm_group_label>DM-/AT-</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 18-75 years either wit type 2 diabetes or non-diabetic, either having
        atherosclerotic vascular events in history or not (ACS, angina pectoris, stroke, TIA,
        clinically symptomatic PAD, atherosclerosis based amputation, stent implantation,
        angiplasty) Diabetes present for more than 1 year.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-75 years either wit type 2 diabetes or non-diabetic, either having
             atherosclerotic vascular events in history or not (ACS, angina pectoris, stroke, TIA,
             clinically symptomatic PAD, atherosclerosis based amputation, stent implantation,
             angiplasty) Diabetes present for more than 1 year.

        Exclusion Criteria:

          -  patient did not signe informed consent

          -  cataract

          -  after cataract operation, after optical operation, after sclera injury

          -  fluorescein angiograpy performed in 6 months

          -  diseases affecting the eye surface( sleritis, Sjogren sy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>2nd Department of Medicine and Nephrological Center</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gergo A Molnar, MD, PhD</last_name>
      <phone>+3672536050</phone>
      <email>gergo.molnar@aok.pte.hu</email>
    </contact>
    <contact_backup>
      <last_name>Eszter Sélley, MD</last_name>
      <phone>+3672536050</phone>
      <email>eszter.selley@aok.pte.hu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>Dr. Gergő Molnár</investigator_full_name>
    <investigator_title>senior lecturer, University of Pécs</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>AGE</keyword>
  <keyword>lens autofluorescence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

